News | Radiation Therapy | August 27, 2019

PTW to Feature New Dosimetry Technology at ASTRO 2019

Offerings will include QA equipment for MR-guided and stereotactic therapy

Beamscan MR 3D water phantom – the first 3-D water phantom for magnetic resonance (MR)-guided radiotherapy

August 27, 2019 — Radiation dosimetry company PTW announced plans to exhibit its full range of radiation therapy dosimetry solutions for acceptance, commissioning, beam data acquisition and patient-specific quality assurance (QA) at the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-19 in Chicago.

In its booth, PTW will exhibit and demonstrate its latest solutions and most recent product developments including:

  • Beamscan MR 3D water phantom – the first 3-D water phantom for magnetic resonance (MR)-guided radiotherapy, available in two ready-to-use models for Elekta Unity and ViewRay MRIdian;
  • Beamscan 3D water phantom – fast to set up and easy to use for all acceptance testing and commissioning needs, now also available for the Halcyon system;
  • Starcheck maxi MR array – a comprehensive solution for machine QA, from high-resolution measurements up to 40 cm x 40 cm in magnetic fields to legally required documentation;
  • MR-conditional detectors – a wide range of PTW's detector brands that are now available for MR dosimetry;
  • Octavius 4-D modular patient and machine QA systems – for the latest radiotherapy techniques, including Halcyon, stereotactic radiosurgery (SRS) and MRgRT. Also introducing the Octavius Detector 1600 SRS for 3-D dose verification of complex SRS/SBRT (stereotactic body radiation therapy) treatment plans;
  • Ruby phantom – a new modular QA phantom with multiple inserts for comprehensive system QA, linear accelerator (linac) QA and patient QA;
  • microSilicon diode detector – the new silicon diode detector for small photon and all electron fields; and
  • Track-it 2.0 QA data management software – a versatile, web-based QA data management software that integrates QA data from different sources, devices and sites into a single platform.

For more information: www.ptwdosimetry.com

Related Content

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...
The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy

An oxygen map image recovered from a mouse undergoing radiation therapy. The luminescent oxygen probe PtG4 is injected during the week of radiation treatment and localizes between the cells of the tumor as illustrated by microscopy (red). Image courtesy of Brian Pogue, PhD

News | Radiation Therapy | February 03, 2020
February 3, 2020 — Oxygen in cancer tumors is known to be a major factor that helps radiation therapy be successful.
News | Clinical Trials | February 03, 2020
February 3, 2020 — Melding the genetic and cellular analysis of tumors with how they appear in medical images could g